Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS
- PMID: 9928727
- DOI: 10.1097/00042560-199901010-00005
Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS
Abstract
Objective: To evaluate the association of ganciclovir (GCV) and foscarnet (PFA) therapy with the outcome of previously diagnosed Kaposi's sarcoma (KS) after initiating antiviral therapy for cytomegalovirus (CMV) end-organ disease.
Design: Retrospective study.
Methods: KS progression was defined as a clinically obvious increase in size of baseline cutaneous or mucosal lesions, a new diagnosis of visceral KS, or initiation of a new systemic antineoplastic regimen or radiation therapy to treat KS. Multivariate analyses of risk of KS progression were calculated for prior duration of KS before initiating CMV treatment, treatment with PFA or GCV, number of weeks treated with PFA or GCV, absolute CD4 lymphocyte count at time of CMV-related disease diagnosis, diagnosis of KS prior to 1991, visceral KS, prior systemic chemotherapy, and prior radiation therapy.
Results: Among 66 patients who received > or = 14 days PFA (N=20) or only GCV (N=46), median time to progression of KS was 211 days (95% confidence interval [CI], 46-578) for patients who received PFA versus 22 days (95% CI, 15-41) for those who received only GCV (p < .001). In the stepwise multivariate analysis, only prior visceral KS (rate ratio [RR]=2.80; 95% CI, 1.07-7.35) and foscarnet therapy (RR = 0.24; 95% CI, 0.11-0.53) were significantly associated with risk of KS progression.
Conclusion: PFA may be an effective therapy for AIDS-related KS; prospective trials are indicated.
Similar articles
-
Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.AIDS. 1996 Sep;10(10):1101-5. AIDS. 1996. PMID: 8874626 Clinical Trial.
-
Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study.J Infect Dis. 1996 Jun;173(6):1477-80. doi: 10.1093/infdis/173.6.1477. J Infect Dis. 1996. PMID: 8648224 Clinical Trial.
-
The treatment of AIDS-related cytomegalovirus disease with ganciclovir and foscarnet association. Three case reports.Recenti Prog Med. 1996 Nov;87(11):545-8. Recenti Prog Med. 1996. PMID: 9122537
-
Is combination antiviral therapy for CMV superior to monotherapy?J Clin Virol. 2006 Apr;35(4):485-8. doi: 10.1016/j.jcv.2005.09.021. Epub 2006 Jan 18. J Clin Virol. 2006. PMID: 16387546 Review.
-
Kaposi's sarcoma: a reevaluation.Recent Results Cancer Res. 1995;139:275-96. Recent Results Cancer Res. 1995. PMID: 7541146 Review.
Cited by
-
Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.Antivir Ther. 2011;16(5):657-66. doi: 10.3851/IMP1810. Antivir Ther. 2011. PMID: 21817187 Free PMC article.
-
Evaluating Kaposi Sarcoma in Kidney Transplant Patients: A Systematic Review and Meta-Analysis.Cureus. 2024 Jan 18;16(1):e52527. doi: 10.7759/cureus.52527. eCollection 2024 Jan. Cureus. 2024. PMID: 38371002 Free PMC article. Review.
-
Designing a multi-epitope based vaccine to combat Kaposi Sarcoma utilizing immunoinformatics approach.Sci Rep. 2019 Feb 21;9(1):2517. doi: 10.1038/s41598-019-39299-8. Sci Rep. 2019. PMID: 30792446 Free PMC article.
-
Tumor Microenvironment Conditioning by Abortive Lytic Replication of Oncogenic γ-Herpesviruses.Adv Exp Med Biol. 2020;1225:127-135. doi: 10.1007/978-3-030-35727-6_9. Adv Exp Med Biol. 2020. PMID: 32030652 Review.
-
Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus.Mol Cancer Ther. 2008 Mar;7(3):712-20. doi: 10.1158/1535-7163.MCT-07-2036. Mol Cancer Ther. 2008. PMID: 18347156 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials